About Pyrroline-5-carboxylate reductase 2
Pyrroline-5-carboxylate reductase 2 (PYCR2) is a protein
from Homo sapiens identified by UniProt accession
Q96C36, 320 residues long.
MolForge cross-references it against 0 known binders and
54 disease associations.
Target properties
| Protein name | Pyrroline-5-carboxylate reductase 2 |
|---|
| UniProt accession | Q96C36 |
|---|
| Gene | PYCR2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 320 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (54)
Diseases linked to this target (Open Targets).
- hypomyelinating leukodystrophy 10 · score 0.73
- Hypomyelinating leukodystrophy with or without oligondontia and/or hypogonadism · score 0.64
- autosomal recessive primary microcephaly · score 0.37
- Intellectual disability · score 0.37
- neurodegenerative disease · score 0.26
- genetic disorder · score 0.19
- Microcephaly · score 0.12
- neoplasm · score 0.09
- glioblastoma multiforme · score 0.08
- mean platelet volume · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96C36-F1 | alphafold | PREDICTED | 89.58 | — |
Amino-acid sequence (320 residues)
MSVGFIGAGQ LAYALARGFT AAGILSAHKI IASSPEMNLP TVSALRKMGV NLTRSNKETV KHSDVLFLAV KPHIIPFILD EIGADVQARH IVVSCAAGVT ISSVEKKLMA FQPAPKVIRC MTNTPVVVQE GATVYATGTH ALVEDGQLLE QLMSSVGFCT EVEEDLIDAV TGLSGSGPAY AFMALDALAD GGVKMGLPRR LAIQLGAQAL LGAAKMLLDS EQHPCQLKDN VCSPGGATIH ALHFLESGGF RSLLINAVEA SCIRTRELQS MADQEKISPA ALKKTLLDRV KLESPTVSTL TPSSPGKLLT RSLALGGKKD
Explore Pyrroline-5-carboxylate reductase 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets